{"gene":"WNK3","run_date":"2026-06-11T09:02:06","timeline":{"discoveries":[{"year":2005,"finding":"Kinase-active WNK3 increases Cl- influx via NKCC1 and inhibits Cl- exit through KCC1 and KCC2; kinase-inactive WNK3 has opposite effects. WNK3 effects are imparted via altered phosphorylation and surface expression of its downstream targets and bypass the normal requirement of altered tonicity for activation of these transporters.","method":"Heterologous expression in Xenopus laevis oocytes; kinase-inactive mutant studies; phosphorylation and surface expression assays","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal gain/loss-of-function experiments with kinase-inactive mutant, multiple transporters tested, replicated across related papers","pmids":["16275911"],"is_preprint":false},{"year":2005,"finding":"Kinase-active WNK3 potently activates both NKCC2 and NCC-mediated transport; kinase-inactive WNK3 potently inhibits both. WNK3 regulates these transporters by altering their expression at the plasma membrane and increases phosphorylation of NKCC2 at Thr-184 and Thr-189.","method":"Coexpression studies in Xenopus oocytes; kinase-inactive mutant; plasma membrane expression assays; phosphorylation assays","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — kinase-active vs. kinase-inactive mutants, surface expression and phosphorylation measured, multiple transporters, replicated in independent labs","pmids":["16275913"],"is_preprint":false},{"year":2006,"finding":"WNK3 completely prevents cell swelling-induced activation of KCC1-KCC4 in Xenopus oocytes. Catalytically inactive WNK3 abolishes cell shrinkage-induced inhibition of KCC1-KCC4, resulting in >100-fold stimulation of K-Cl cotransport. This activation is abolished by calyculin A and cyclosporine A (protein phosphatase 1 and 2B inhibitors), indicating WNK3 acts via a phosphatase-dependent pathway to regulate KCCs.","method":"Heterologous expression in Xenopus oocytes; kinase-inactive mutant; pharmacological phosphatase inhibitors (calyculin A, cyclosporine A)","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — kinase-active and kinase-inactive mutants tested on multiple KCC isoforms, phosphatase involvement validated with two pharmacological inhibitors","pmids":["16446421"],"is_preprint":false},{"year":2008,"finding":"Intracellular chloride depletion activates NKCC2 by promoting phosphorylation of three conserved threonines (T96, T101, T111). This chloride-sensitive activation requires WNK3 upstream of SPAK; elimination of WNK3's SPAK-binding motif prevents NKCC2 activation, as does catalytically inactive WNK3.","method":"Heterologous expression in Xenopus laevis oocytes; KCC2 co-expression and hypotonic stress for Cl- depletion; threonine-to-alanine mutagenesis; SPAK-binding motif deletion; kinase-inactive mutant","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 / Strong — mutagenesis of phosphorylation sites and binding motifs with functional readouts, multiple orthogonal approaches in one rigorous study","pmids":["18550832"],"is_preprint":false},{"year":2005,"finding":"WNK3 inhibits the renal K+ channel ROMK1 >5.5-fold by reducing its plasmalemmal surface expression. This inhibition is independent of WNK3's catalytic activity and is mediated by WNK3's carboxyl terminus. A kinase-inactivating point mutation enhances ROMK1 inhibition >2.5-fold. WNK3 had no effect on paracellular Cl- flux or ENaC-mediated currents.","method":"Coexpression in Xenopus laevis oocytes; kinase-inactive and domain mutants; MDCK II paracellular flux assay; surface expression analysis","journal":"The Journal of physiology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — reciprocal gain/loss-of-function, domain mapping, multiple channel targets tested with controls, specificity shown by negative result on KCNQ1/KCNE1","pmids":["16357011"],"is_preprint":false},{"year":2006,"finding":"Endogenous WNK3 is an active protein kinase when immunoprecipitated from cells. WNK3 overexpression increases HeLa cell survival by delaying apoptosis onset; WNK3 knockdown by RNAi accelerates apoptotic response and promotes caspase-3 activation. The mechanism involves interaction of WNK3 with procaspase-3 and heat-shock protein 70.","method":"Immunoprecipitation kinase assay; overexpression; RNAi knockdown; caspase-3 activation assays; co-immunoprecipitation with procaspase-3 and HSP70","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — endogenous kinase activity confirmed by IP-kinase assay, RNAi and overexpression with functional readout, co-IP binding partners identified, single lab","pmids":["16501604"],"is_preprint":false},{"year":2008,"finding":"WNK3 positively regulates TRPV5 and TRPV6 epithelial calcium channels in a kinase-dependent manner, increasing TRPV5-mediated Ca2+ uptake by ~83%. The kinase domain alone is sufficient; D294A kinase-inactive mutation abolishes the effect. WNK3 increases the complexly glycosylated, plasma membrane-expressed form of TRPV5 via enhanced delivery through the secretory pathway, blocked by microtubule inhibitor colchicine.","method":"Coexpression in Xenopus laevis oocytes; kinase-inactive D294A mutant; kinase domain truncation; Ca2+ uptake assay; voltage-clamp; plasma membrane expression and exocytosis assays; colchicine treatment","journal":"American journal of physiology. Renal physiology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — reconstitution in oocytes with mutagenesis (D294A), domain deletion, trafficking assay with pharmacological inhibitor, multiple orthogonal methods in one study","pmids":["18768590"],"is_preprint":false},{"year":2008,"finding":"The amino-terminal domain of WNK3 (not the kinase or carboxyl domain) determines whether a WNK kinase activates or inhibits NCC. Chimeras swapping amino- or carboxyl-terminal domains between WNK3 and WNK4 show that the amino terminus governs activating vs. inhibiting properties toward NCC.","method":"WNK3/WNK4 chimera construction and coexpression in Xenopus oocytes; NCC transport assays","journal":"American journal of physiology. Renal physiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — domain-swap chimeras with functional readout, multiple chimera constructs, single lab","pmids":["18701621"],"is_preprint":false},{"year":2009,"finding":"Renal and brain splice isoforms of WNK3 (differing by exons 18 and 22) have opposite effects on NCC: the renal isoform increases NCC expression/activity while the brain isoform decreases it. Kinase-inactivating mutation in renal WNK3 reverses its effect. Brain WNK3 acts in tandem with SPAK, whereas renal WNK3 upregulates NCC through a SPAK-independent pathway.","method":"Expression in Xenopus oocytes; kinase-dead mutant; kinase-dead SPAK coexpression; NCC surface expression and transport assays","journal":"Journal of the American Society of Nephrology : JASN","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple splice variants compared, kinase-dead mutants, SPAK-dependence tested, single lab","pmids":["19470686"],"is_preprint":false},{"year":2011,"finding":"WNK3 knockout mice show no significant decrease in phosphorylation or expression of OSR1, SPAK, NKCC2, or NCC under normal or low-salt diets, indicating WNK3 has only a minor role in regulating these transporters in vivo in the kidney. WNK1 expression was slightly elevated in knockout mice on low-salt diet, suggesting compensatory upregulation.","method":"WNK3 knockout mouse generation; immunoblotting for pOSR1, pSPAK, pNKCC2, pNCC; urine electrolyte measurements; blood pressure measurement","journal":"Biology open","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic knockout with multiple molecular and physiological readouts; negative result for renal transporter phosphorylation is itself mechanistically informative, single lab","pmids":["23213404"],"is_preprint":false},{"year":2011,"finding":"In glioma cells, WNK3 co-localizes and co-immunoprecipitates with NKCC1 upon cell volume changes. Stable knockdown of WNK3 completely abolishes bumetanide-sensitive NKCC1 activity and reduces invasive capacity across Transwell barriers.","method":"Co-immunoprecipitation; shRNA knockdown; bumetanide-sensitive cell volume regulation assay; Transwell invasion assay","journal":"American journal of physiology. Cell physiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP plus functional shRNA knockdown with two orthogonal readouts (volume regulation and invasion), single lab","pmids":["21813709"],"is_preprint":false},{"year":2012,"finding":"WNK3 binds Fox-1 (neuronal mRNA splicing factor) and inhibits its splicing activity in a kinase activity-dependent manner. WNK3 phosphorylates Fox-1 without changing its RNA binding capacity; instead, WNK3 increases the cytoplasmic localization of Fox-1, thereby suppressing Fox-1-dependent splicing.","method":"Co-immunoprecipitation; in vitro phosphorylation assay; subcellular localization studies; splicing reporter assays; kinase-inactive mutant comparisons","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — binding confirmed by co-IP, phosphorylation shown, subcellular redistribution measured, functional splicing readout, single lab","pmids":["23027929"],"is_preprint":false},{"year":2012,"finding":"WNK3's effects on NCC and other CCCs require interaction with SPAK via specific RFxV binding motifs. The F242A mutation in the first SPAK-binding site of WNK3 abolishes effects on all tested cotransporters; F1337A eliminates effect on NKCC2 but preserves effects on NCC, NKCC1, and KCC4; F873A has no consequence. WNK3 can promote NCC phosphorylation at T58 even without the NCC SPAK-binding site, suggesting WNK3 binds both SPAK and NCC to promote phosphorylation.","method":"Site-directed mutagenesis of SPAK binding motifs; expression in Xenopus laevis oocytes; transport assays; phosphorylation assays","journal":"Cellular physiology and biochemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — systematic mutagenesis of three binding sites with functional readouts on multiple cotransporters, mechanistic conclusions supported by multiple mutants, single lab","pmids":["22415098"],"is_preprint":false},{"year":2013,"finding":"In mouse aorta, the WNK3-SPAK-NKCC1 phosphorylation cascade is regulated by dietary salt intake through angiotensin II acting via the AT1 receptor. In WNK3 knockout mice, low-salt diet and angiotensin II infusion fail to increase SPAK/NKCC1 phosphorylation, demonstrating WNK3 dependence. Angiotensin II-induced blood pressure increases are diminished in WNK3 knockout mice.","method":"WNK3 knockout mice; dietary salt manipulation; angiotensin II infusion; AT1 receptor antagonist (valsartan); immunoblotting for pSPAK, pNKCC1; blood pressure measurement","journal":"Hypertension","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic knockout with pharmacological validation, multiple physiological readouts, receptor antagonist used to place WNK3 downstream of AT1, single lab but multiple orthogonal approaches","pmids":["24019400"],"is_preprint":false},{"year":2013,"finding":"LINGO-1 co-localizes and co-precipitates with WNK3 in cultured cortical neurons and brain tissue. Nogo66 stimulation enhances this co-association and reduces WNK3 kinase activity. LINGO-1 binding to WNK3's intracellular domain reduces WNK3 kinase activity, thereby promoting neuronal apoptosis.","method":"Co-immunoprecipitation; co-localization immunofluorescence; kinase activity assay; shRNA knockdown; Nogo66 stimulation; LINGO-1 intracellular domain construct","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal co-IP, kinase activity assay, in vitro and in vivo evidence, single lab with multiple methods","pmids":["23482566"],"is_preprint":false},{"year":2013,"finding":"In WNK3-deficient mice, WNK1 is markedly upregulated while WNK4 expression remains similar, indicating that WNK1/SPAK axis compensates for WNK3 loss in the kidney. Under low-salt diet, pSPAK/OSR1, pNKCC2, and pNCC levels in WNK3-/- exceed those in wild-type, confirming compensatory activation of WNK3-independent pathways.","method":"WNK3 knockout mice; immunoblotting for WNK1, WNK4, pSPAK/OSR1, pNKCC2, pNCC; hydrochlorothiazide diuretic response; dietary salt manipulation","journal":"American journal of physiology. Renal physiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic knockout with molecular and pharmacological validation, single lab","pmids":["23427142"],"is_preprint":false},{"year":2014,"finding":"NEDD4-2 was identified as a WNK3-interacting partner via GST pulldown of WNK3's N-terminal domain followed by LC-MS/MS, validated by co-immunoprecipitation in HEK293 cells. WNK3 interaction with NEDD4-2 does not involve the PY-like motif. WNK3 does not ubiquitylate NEDD4-2 or phosphorylate NEDD4-2 on S222/S328, and does not regulate NCC-NEDD4-2 interaction. WNK3 can overcome SGK1-resistant NEDD4-2-mediated inhibition of NCC via a SPAK-independent mechanism (F242A mutation blocks NCC activation but not NEDD4-2 inhibitory reversal).","method":"GST pulldown with LC-MS/MS; co-immunoprecipitation in HEK293 cells; ubiquitylation assay; phosphorylation assay; Xenopus oocyte expression with SPAK-binding mutant WNK3-F242A","journal":"American journal of physiology. Renal physiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — GST pulldown/MS plus co-IP validation, functional oocyte assays with domain mutant, single lab, multiple orthogonal methods","pmids":["24920754"],"is_preprint":false},{"year":2015,"finding":"In ischemic stroke (transient MCAO), WNK3 knockout mice exhibit significantly decreased infarct volume and axonal demyelination, reduced cerebral edema, and accelerated neurological recovery. The neuroprotective phenotype is associated with decreased hyperphosphorylation of SPAK/OSR1 catalytic T-loop and of NKCC1 stimulatory sites Thr203/Thr207/Thr212, and decreased cell surface expression of NKCC1. siRNA knockdown of SPAK/OSR1 also increased tolerance of neurons and oligodendrocytes to in vitro ischemia, confirming WNK3-SPAK/OSR1-NKCC1 as the operative cascade.","method":"WNK3 knockout mice; transient MCAO; infarct volume, edema, demyelination assessment; immunoblotting and immunostaining for pSPAK/OSR1, pNKCC1, NKCC1 surface expression; oxygen-glucose deprivation/reoxygenation in neurons and oligodendrocytes; siRNA knockdown","journal":"Stroke","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic knockout plus siRNA knockdown of downstream target, molecular readouts of the cascade, in vitro and in vivo concordant evidence, multiple cell types","pmids":["26069258"],"is_preprint":false},{"year":2016,"finding":"WNK3 enhances NCC protein expression by increasing NCC protein synthesis (not via lysosomal degradation pathway). WNK3 reduces ERK1/2 phosphorylation, and knockdown of ERK1/2 expression reverses WNK3-mediated increase in NCC, indicating WNK3 acts through an ERK1/2 signaling pathway to upregulate NCC.","method":"Overexpression and siRNA knockdown in Cos-7 and mouse distal convoluted tubule cells; cycloheximide pulse-chase assay; bafilomycin A1 treatment; ERK1/2 knockdown; Western blot","journal":"Nephron","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple pharmacological and genetic interventions, CHX pulse assay establishes synthesis mechanism, ERK1/2 knockdown confirms pathway, single lab","pmids":["27467688"],"is_preprint":false},{"year":2016,"finding":"Deletion of the WNK3-SPAK kinase complex in mice (WNK3 KO and SPAK heterozygous or KO) each produce >50% reduction in infarct size and cerebral edema, significantly less demyelination, and improved neurological outcomes after MCAO stroke, establishing the WNK3-SPAK complex as the operative signaling unit mediating ischemic brain injury.","method":"WNK3 KO, SPAK heterozygous and SPAK KO mice; transient MCAO; MRI diffusion tensor imaging; immunofluorescence; neurological deficit scoring up to 14 days","journal":"Journal of cerebral blood flow and metabolism","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic evidence from three distinct mouse genotypes (WNK3 KO, SPAK het, SPAK KO) with concordant results, multiple imaging and behavioral readouts","pmids":["26861815"],"is_preprint":false},{"year":2020,"finding":"WNK3 is not sensitive to intracellular chloride concentration but is regulated by changes in extracellular tonicity (cell volume changes). Elimination of the chloride-binding site in WNK3 does not affect its activity toward NCC. Chimeric WNK3/WNK4 analysis suggests sequences within the carboxy-terminal end modulate chloride affinity. In contrast, WNK4 is chloride-sensitive but not regulated by cell volume.","method":"Xenopus oocyte expression system; chloride-binding site mutagenesis; WNK3/WNK4 chimeric protein constructs; tonicity and Cl- concentration manipulation; NCC transport assays","journal":"American journal of physiology. Cell physiology","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — chimera domain mapping plus active-site mutagenesis, functional assays with controlled conditions, single lab","pmids":["32579473"],"is_preprint":false},{"year":2021,"finding":"WNK3 knockdown in hippocampal neurons hyperpolarizes the GABAA reversal potential (EGABA) in mature (DIV13-15) but not immature (DIV6-8) neurons. This effect is mediated through reduced phosphorylation of KCC2 at the membrane (increased KCC2 activity), reversed by KCC2 inhibitor VU024055. WNK3 knockdown also causes morphological changes and increased intrinsic excitability in mature neurons.","method":"shRNA knockdown in embryonic hippocampal neurons; gramicidin-perforated patch-clamp; immunoblotting for KCC2 phosphorylation; KCC2 inhibitor (VU024055); membrane surface expression analysis","journal":"Frontiers in molecular neuroscience","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — electrophysiology combined with biochemical and pharmacological rescue, single lab, multiple methods","pmids":["34858138"],"is_preprint":false},{"year":2022,"finding":"WNK3 knockout mice show elevated intracellular Cl- in layer V prefrontal cortex pyramidal neurons (EGABA depolarized by 6 mV, corresponding to ~4 mM higher [Cl-]i). KO neurons exhibit increased inwardly rectifying K+ (Kir channel) conductance, hyperpolarized resting membrane potential, and increased firing threshold. Introducing active WNK3 into KO neurons reverses these changes. The KCC2 activator CLP290 reverses enhanced IRK conductance in KO neurons, linking WNK3 and KCC2 in resting K+ conductance regulation. WNK3 KO mice show behavioral deficits in prepulse inhibition.","method":"WNK3 KO mice; gramicidin-perforated patch-clamp in acute slices; intracellular active WNK3 injection; CLP290 (KCC2 activator); immunoblotting for pSPAK, pOSR1, pNKCC1, pKCC2; mEPSC/mIPSC recording; prepulse inhibition behavioral test","journal":"Frontiers in molecular neuroscience","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO with electrophysiology, pharmacological rescue, and acute kinase reintroduction, multiple orthogonal methods, single lab","pmids":["36311015"],"is_preprint":false},{"year":2022,"finding":"WNK3 pathogenic missense variants (p.Pro204Arg, p.Leu300Ser, p.Glu607Val) localize to the catalytic domain and impede the inhibitory phosphorylation of neuronal KCC2 at threonine 1007, a site critically regulated during development of synaptic inhibition, causing X-linked intellectual disability.","method":"Exome/genome sequencing of intellectual disability families; functional assays of KCC2 T1007 phosphorylation with disease-associated WNK3 variants","journal":"Genetics in medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — disease-causing variants tested in functional phosphorylation assay, multiple families with cosegregation, mechanistic link to KCC2 phosphorylation established","pmids":["35678782"],"is_preprint":false},{"year":2022,"finding":"WNK3 is a positive regulator of PD-L1 expression in tumor cells via a kinase-dependent mechanism. Kinase-dead WNK3 mutant fails to elevate PD-L1 levels. WNK3 regulates PD-L1 transcription through the JNK/c-JUN pathway.","method":"Pooled shRNA screening; kinase-dead mutant; co-culture of cancer and immune cells; cytokine and cytolytic enzyme secretion assays; WNK463 pan-WNK inhibitor; MC38 syngeneic mouse tumor model; c-JUN pathway analysis","journal":"Experimental & molecular medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — shRNA screen validated with kinase-dead mutant and pharmacological inhibitor, in vivo syngeneic model, pathway identification via c-JUN, single lab","pmids":["36357569"],"is_preprint":false},{"year":2022,"finding":"WNK3 co-localizes and interacts with the circadian clock protein PER1 in the suprachiasmatic nucleus. WNK3 phosphorylates PER1 to promote its degradation. WNK3 knockdown in rat SCN alters sleep patterns.","method":"Co-localization and co-immunoprecipitation in SCN; in vitro kinase assay (PER1 phosphorylation); shRNA knockdown in vivo; sleep pattern analysis","journal":"American journal of translational research","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, co-IP plus in vitro phosphorylation, limited mechanistic follow-up, abstract-level description of methods","pmids":["35273702"],"is_preprint":false}],"current_model":"WNK3 is a serine-threonine kinase that acts as a master regulator of intracellular chloride homeostasis and cell volume by coordinately activating Na-(K)-Cl cotransporters (NKCC1, NKCC2, NCC) and inhibiting K-Cl cotransporters (KCC1–KCC4) through its kinase activity and interaction with the downstream SPAK/OSR1 kinases via RFxV binding motifs; it also regulates ROMK1 surface expression via a kinase-independent carboxyl-terminal mechanism, modulates neuronal Fox-1 splicing factor localization, promotes cell survival by interacting with procaspase-3, regulates PD-L1 via JNK/c-JUN signaling, phosphorylates the circadian protein PER1, and mediates ischemic brain edema through the WNK3-SPAK-NKCC1 cascade, with loss-of-function variants in its catalytic domain causing X-linked intellectual disability through impaired KCC2 phosphorylation."},"narrative":{"mechanistic_narrative":"WNK3 is a serine-threonine protein kinase that functions as a coordinate regulator of cation-chloride cotransporters, setting intracellular chloride concentration and cell volume by reciprocally controlling Na-(K)-Cl cotransporters and K-Cl cotransporters: kinase-active WNK3 activates NKCC1, NKCC2 and NCC by increasing their surface expression and stimulatory-site phosphorylation while inhibiting KCC1–KCC4, and the catalytically inactive kinase produces the opposite effects, bypassing the normal tonicity requirement for transporter activation [PMID:16275911, PMID:16275913, PMID:16446421]. Its activation of cotransporters operates upstream of the SPAK/OSR1 kinases through RFxV-type binding motifs, where site-specific mutations (F242A, F1337A) selectively abolish effects on individual cotransporters, and WNK3 promotes target phosphorylation by binding both SPAK and the cotransporter [PMID:18550832, PMID:22415098]. WNK3 itself is regulated by extracellular tonicity/cell volume rather than by direct intracellular chloride sensing, distinguishing it from chloride-sensitive WNK4 [PMID:32579473]. In neurons WNK3 controls GABAergic signaling by restraining KCC2 via inhibitory phosphorylation, so its loss hyperpolarizes the GABAA reversal potential and lowers intracellular chloride, and pathogenic catalytic-domain missense variants that impair KCC2 Thr1007 phosphorylation cause X-linked intellectual disability [PMID:34858138, PMID:36311015, PMID:35678782]. The WNK3-SPAK-NKCC1 cascade also drives ischemic brain injury, as WNK3 or SPAK deletion reduces infarct volume, cerebral edema and demyelination after stroke [PMID:26069258, PMID:26861815]. Beyond its core cotransporter role, WNK3 regulates ROMK1 surface expression through a kinase-independent C-terminal mechanism [PMID:16357011], activates TRPV5/TRPV6 calcium channels via the secretory pathway [PMID:18768590], modulates renal NCC abundance through ERK1/2 and NEDD4-2 [PMID:24920754, PMID:27467688], promotes cell survival through interaction with procaspase-3 [PMID:16501604], regulates neuronal Fox-1 splicing-factor localization [PMID:23027929], controls tumor PD-L1 via JNK/c-JUN signaling [PMID:36357569], and phosphorylates the circadian protein PER1 [PMID:35273702]; in vivo, however, renal cotransporter regulation is largely dispensable, with WNK1 compensating for WNK3 loss in the kidney [PMID:23213404, PMID:23427142].","teleology":[{"year":2005,"claim":"Established WNK3 as a bidirectional switch over chloride transport, answering whether a single kinase could coordinately activate Na-coupled and inhibit K-coupled chloride cotransporters.","evidence":"Kinase-active and kinase-inactive WNK3 expressed with NKCC1/NKCC2/NCC and KCC1–KCC2 in Xenopus oocytes with phosphorylation and surface-expression readouts","pmids":["16275911","16275913"],"confidence":"High","gaps":["Performed in a heterologous oocyte system; physiological relevance in native tissue untested at this stage","Direct vs. indirect phosphorylation of transporters not distinguished"]},{"year":2006,"claim":"Showed WNK3 regulates KCCs through a phosphatase-dependent pathway, clarifying that WNK3 opposes the cell-volume-dependent dephosphorylation that activates K-Cl cotransport.","evidence":"Oocyte expression of KCC1–KCC4 with kinase-inactive WNK3 and PP1/PP2B inhibitors (calyculin A, cyclosporine A)","pmids":["16446421"],"confidence":"High","gaps":["Identity of the responsible phosphatase not pinned down","Whether WNK3 acts directly on the phosphatase or on the transporter unresolved"]},{"year":2005,"claim":"Defined a kinase-independent function of WNK3, distinguishing its catalytic activity from a separate C-terminal mechanism that suppresses ROMK1 surface expression.","evidence":"Coexpression of ROMK1 with kinase-inactive and domain-mutant WNK3 in oocytes, with paracellular and ENaC controls","pmids":["16357011"],"confidence":"High","gaps":["C-terminal effector mediating ROMK1 trafficking not identified","Physiological role in renal K+ handling untested"]},{"year":2006,"claim":"Demonstrated endogenous WNK3 kinase activity and a pro-survival role, expanding WNK3 function beyond ion transport into apoptosis regulation.","evidence":"IP-kinase assay, overexpression/RNAi in HeLa cells with caspase-3 readout, and co-IP with procaspase-3 and HSP70","pmids":["16501604"],"confidence":"Medium","gaps":["Whether WNK3 phosphorylates procaspase-3 not established","Single-lab co-IP without reciprocal or structural validation"]},{"year":2008,"claim":"Established WNK3 as an upstream component of a chloride-sensitive SPAK cascade and mapped phosphorylation sites, defining the signaling architecture controlling NKCC2.","evidence":"Oocyte expression with NKCC2 threonine-to-alanine mutagenesis, SPAK-binding motif deletion, and kinase-inactive WNK3","pmids":["18550832"],"confidence":"High","gaps":["Direct phosphorylation of SPAK by WNK3 not shown biochemically here","In vivo chloride-sensing mechanism unresolved"]},{"year":2008,"claim":"Localized the activating-vs-inhibiting determinant to the WNK3 amino-terminal domain and showed kinase-dependent positive regulation of TRPV5/TRPV6, broadening WNK3 targets to calcium channels.","evidence":"WNK3/WNK4 chimeras and NCC assays; oocyte TRPV5/TRPV6 Ca2+ uptake with D294A mutant, domain truncation, and colchicine","pmids":["18701621","18768590"],"confidence":"High","gaps":["Molecular basis by which the N-terminus dictates activating vs inhibiting output not defined","Whether TRPV channels are direct substrates unknown"]},{"year":2009,"claim":"Revealed isoform-specific and SPAK-dependence differences, showing renal and brain WNK3 splice variants exert opposite effects on NCC through distinct pathways.","evidence":"Oocyte expression of renal vs brain WNK3 isoforms with kinase-dead WNK3 and kinase-dead SPAK coexpression","pmids":["19470686"],"confidence":"Medium","gaps":["Mechanism by which exons 18/22 invert function not resolved","Tissue isoform expression patterns not validated in vivo"]},{"year":2011,"claim":"Tested the in vivo requirement for WNK3 in renal transporter regulation and found it largely dispensable, prompting a compensation model.","evidence":"WNK3 knockout mice with immunoblotting of pSPAK/OSR1/NKCC2/NCC, urine electrolytes, and blood pressure under salt diets","pmids":["23213404"],"confidence":"Medium","gaps":["Compensatory mechanism only inferred from WNK1 upregulation","Possible developmental compensation not excluded"]},{"year":2011,"claim":"Linked WNK3-NKCC1 signaling to a disease-relevant cellular behavior, showing WNK3 supports volume regulation and invasion in glioma.","evidence":"Co-IP of WNK3 with NKCC1 plus shRNA knockdown with bumetanide-sensitive volume and Transwell invasion assays","pmids":["21813709"],"confidence":"Medium","gaps":["Whether invasion effect is solely NKCC1-dependent unclear","Single-lab functional data"]},{"year":2012,"claim":"Mapped the RFxV SPAK-binding motifs that govern target selectivity and identified a non-canonical role in mRNA splicing, defining how WNK3 selects among cotransporters and uncovering Fox-1 regulation.","evidence":"Systematic F242A/F1337A/F873A mutagenesis with cotransporter assays; co-IP, in vitro phosphorylation, and splicing reporters for Fox-1","pmids":["22415098","23027929"],"confidence":"High","gaps":["How the same motifs confer different specificity for each cotransporter not fully explained","Fox-1 splicing role tested in heterologous reporter context only"]},{"year":2013,"claim":"Placed WNK3 downstream of angiotensin II/AT1 signaling in vasculature and identified an inhibitory kinase regulator, situating WNK3 within hormonal blood-pressure control and neuronal apoptosis.","evidence":"WNK3 KO mice with salt/AngII manipulation and valsartan; LINGO-1 co-IP, Nogo66 stimulation, and kinase-activity assays in neurons","pmids":["24019400","23482566"],"confidence":"High","gaps":["Direct vascular substrate of the WNK3-SPAK-NKCC1 cascade not defined","Mechanism by which LINGO-1 binding inhibits kinase activity unresolved"]},{"year":2013,"claim":"Confirmed WNK1/SPAK axis compensation for renal WNK3 loss, reconciling robust oocyte effects with a minor in vivo kidney phenotype.","evidence":"WNK3 KO mice with immunoblotting of WNK1/WNK4 and phospho-transporters plus hydrochlorothiazide response under salt diets","pmids":["23427142"],"confidence":"Medium","gaps":["Mechanism of WNK1 upregulation upon WNK3 loss not established","Extent of functional redundancy across nephron segments unclear"]},{"year":2014,"claim":"Identified NEDD4-2 as an N-terminal partner and showed WNK3 reverses NEDD4-2-mediated NCC inhibition through a non-catalytic, SPAK-independent route, distinguishing this from its canonical cascade.","evidence":"GST pulldown/LC-MS/MS and co-IP in HEK293; ubiquitylation/phosphorylation assays and oocyte assays with WNK3-F242A","pmids":["24920754"],"confidence":"Medium","gaps":["Molecular mechanism by which WNK3 antagonizes NEDD4-2 not defined","Single-lab interaction without structural mapping"]},{"year":2015,"claim":"Established WNK3-SPAK/OSR1-NKCC1 as the operative cascade driving ischemic brain edema and injury, providing a therapeutic rationale.","evidence":"WNK3 KO mice with MCAO, infarct/edema/demyelination readouts, cascade phospho-immunoblotting, and OGD with SPAK/OSR1 siRNA in neurons/oligodendrocytes","pmids":["26069258"],"confidence":"High","gaps":["Upstream trigger activating WNK3 during ischemia not identified","Cell-type-specific contributions not fully dissected"]},{"year":2016,"claim":"Uncovered a transcriptional/translational arm of WNK3 NCC regulation via ERK1/2 and confirmed the WNK3-SPAK complex as the stroke effector unit using complementary genetics.","evidence":"Overexpression/knockdown in DCT cells with CHX pulse-chase and ERK1/2 knockdown; WNK3 KO, SPAK het and SPAK KO mice with MCAO and DTI imaging","pmids":["27467688","26861815"],"confidence":"High","gaps":["How WNK3 lowers ERK1/2 phosphorylation mechanistically unknown","Whether ERK1/2 arm operates in vivo not tested"]},{"year":2020,"claim":"Redefined WNK3 regulation as cell-volume/tonicity-responsive rather than intracellular-chloride-sensitive, separating it mechanistically from WNK4.","evidence":"Oocyte NCC assays with WNK3 chloride-binding-site mutagenesis and WNK3/WNK4 chimeras under controlled tonicity and Cl-","pmids":["32579473"],"confidence":"Medium","gaps":["The volume-sensing element within the C-terminus not identified","Physiological signal coupling volume to WNK3 activity unknown"]},{"year":2021,"claim":"Demonstrated WNK3 controls GABAergic chloride homeostasis in mature neurons via KCC2 phosphorylation, defining its role in synaptic inhibition development.","evidence":"shRNA knockdown in hippocampal neurons with perforated patch-clamp EGABA, KCC2 phospho-immunoblotting, and KCC2 inhibitor VU024055 rescue","pmids":["34858138"],"confidence":"Medium","gaps":["Why the effect is age-dependent (mature vs immature) not explained","Direct WNK3 phosphorylation of KCC2 not shown biochemically here"]},{"year":2022,"claim":"Extended WNK3-KCC2 regulation to intrinsic excitability and resting K+ conductance in cortical neurons and tied catalytic-domain variants to X-linked intellectual disability, establishing a disease mechanism.","evidence":"WNK3 KO mice with patch-clamp, active-WNK3 reintroduction, CLP290 rescue, and behavioral testing; ID-family sequencing with KCC2 T1007 phosphorylation assays of variants","pmids":["36311015","35678782"],"confidence":"Medium","gaps":["Link between altered Cl-/excitability and cognitive phenotype not directly demonstrated","Variant functional assays in patient-derived neurons not performed"]},{"year":2022,"claim":"Identified additional kinase-dependent roles in tumor immune evasion and circadian regulation, broadening WNK3 substrates beyond ion transport.","evidence":"shRNA screen, kinase-dead mutant, WNK463 inhibitor and MC38 model with c-JUN analysis for PD-L1; co-IP and in vitro PER1 phosphorylation with SCN shRNA knockdown and sleep analysis","pmids":["36357569","35273702"],"confidence":"Low","gaps":["PER1/circadian role rests on a single low-confidence study without reconstitution","How WNK3 engages the JNK/c-JUN pathway to regulate PD-L1 transcription not mechanistically defined"]},{"year":null,"claim":"How extracellular tonicity is transduced into WNK3 catalytic activation, and how a single kinase achieves opposite, target-specific outputs across cotransporters, channels, and splicing/transcriptional substrates, remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No structural model of the volume-sensing C-terminus","Mechanism converting one kinase into bidirectional transporter control unknown","Direct vs indirect phosphorylation for several proposed substrates undetermined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[0,1,3,11,23,25]},{"term_id":"GO:0016740","term_label":"transferase activity","supporting_discovery_ids":[0,3,5,12]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[2,4,16]}],"localization":[{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[11]},{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[11]}],"pathway":[{"term_id":"R-HSA-382551","term_label":"Transport of small molecules","supporting_discovery_ids":[0,1,2,3,6]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[13,18,24]},{"term_id":"R-HSA-112316","term_label":"Neuronal System","supporting_discovery_ids":[21,22,23]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[5,14]}],"complexes":["WNK3-SPAK kinase complex"],"partners":["SPAK","OSR1","NKCC1","NCC","KCC2","NEDD4-2","LINGO-1","PER1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q9BYP7","full_name":"Serine/threonine-protein kinase WNK3","aliases":["Protein kinase lysine-deficient 3","Protein kinase with no lysine 3"],"length_aa":1800,"mass_kda":198.4,"function":"Serine/threonine-protein kinase component of the WNK3-SPAK/OSR1 kinase cascade, which plays an important role in the regulation of electrolyte homeostasis and regulatory volume increase in response to hyperosmotic stress (PubMed:16275911, PubMed:16275913, PubMed:16501604, PubMed:22989884, PubMed:36318922). WNK3 mediates regulatory volume increase in response to hyperosmotic stress by acting as a molecular crowding sensor, which senses cell shrinkage and mediates formation of a membraneless compartment by undergoing liquid-liquid phase separation (PubMed:36318922). The membraneless compartment concentrates WNK3 with its substrates, OXSR1/OSR1 and STK39/SPAK, promoting WNK3-dependent phosphorylation and activation of downstream kinases OXSR1/OSR1 and STK39/SPAK (PubMed:22989884). Following activation, OXSR1/OSR1 and STK39/SPAK catalyze phosphorylation of ion cotransporters SLC12A1/NKCC2, SLC12A2/NKCC1, SLC12A3/NCC, SLC12A4/KCC1, SLC12A5/KCC2 or SLC12A6/KCC3, regulating their activity (PubMed:16275911, PubMed:16275913). Phosphorylation of Na-K-Cl cotransporters SLC12A2/NKCC1 and SLC12A2/NKCC1 promote their activation and ion influx; simultaneously, phosphorylation of K-Cl cotransporters SLC12A4/KCC1, SLC12A5/KCC2 and SLC12A6/KCC3 inhibits its activity, blocking ion efflux (PubMed:16275911, PubMed:16275913, PubMed:16357011, PubMed:19470686, PubMed:21613606). Phosphorylates WNK4, possibly regulating the activity of SLC12A3/NCC (PubMed:17975670). May also phosphorylate NEDD4L (PubMed:20525693). Also acts as a scaffold protein independently of its protein kinase activity: negatively regulates cell membrane localization of various transporters and channels, such as KCNJ1 and SLC26A9 (PubMed:16357011, PubMed:17673510). Increases Ca(2+) influx mediated by TRPV5 and TRPV6 by enhancing their membrane expression level via a kinase-dependent pathway (PubMed:18768590)","subcellular_location":"Cytoplasm","url":"https://www.uniprot.org/uniprotkb/Q9BYP7/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/WNK3","classification":"Not Classified","n_dependent_lines":2,"n_total_lines":1208,"dependency_fraction":0.0016556291390728477},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"HMGN5","stoichiometry":0.2},{"gene":"OXSR1","stoichiometry":0.2},{"gene":"PPM1G","stoichiometry":0.2},{"gene":"WNK1","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/WNK3","total_profiled":1310},"omim":[{"mim_id":"605232","title":"PROTEIN KINASE, LYSINE-DEFICIENT 1; WNK1","url":"https://www.omim.org/entry/605232"},{"mim_id":"601844","title":"PROTEIN KINASE, LYSINE-DEFICIENT 4; WNK4","url":"https://www.omim.org/entry/601844"},{"mim_id":"309610","title":"PRIETO SYNDROME; PRS","url":"https://www.omim.org/entry/309610"},{"mim_id":"300358","title":"PROTEIN KINASE, LYSINE-DEFICIENT 3; WNK3","url":"https://www.omim.org/entry/300358"},{"mim_id":"300263","title":"INTELLECTUAL DEVELOPMENTAL DISORDER, X-LINKED, SYNDROMIC, SIDERIUS TYPE; MRXSSD","url":"https://www.omim.org/entry/300263"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Vesicles","reliability":"Approved"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in some","driving_tissues":[{"tissue":"epididymis","ntpm":11.1},{"tissue":"testis","ntpm":9.2}],"url":"https://www.proteinatlas.org/search/WNK3"},"hgnc":{"alias_symbol":[],"prev_symbol":["PRKWNK3"]},"alphafold":{"accession":"Q9BYP7","domains":[{"cath_id":"3.30.200.20","chopping":"132-230","consensus_level":"medium","plddt":85.0766,"start":132,"end":230},{"cath_id":"1.10.510.10","chopping":"231-406","consensus_level":"medium","plddt":88.4377,"start":231,"end":406},{"cath_id":"3.10.20.90","chopping":"409-497","consensus_level":"medium","plddt":86.3417,"start":409,"end":497},{"cath_id":"3.10.20.90","chopping":"742-823_1330-1342","consensus_level":"medium","plddt":82.8371,"start":742,"end":1342}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9BYP7","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q9BYP7-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q9BYP7-F1-predicted_aligned_error_v6.png","plddt_mean":47.41},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=WNK3","jax_strain_url":"https://www.jax.org/strain/search?query=WNK3"},"sequence":{"accession":"Q9BYP7","fasta_url":"https://rest.uniprot.org/uniprotkb/Q9BYP7.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q9BYP7/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9BYP7"}},"corpus_meta":[{"pmid":"18550832","id":"PMC_18550832","title":"Regulation of NKCC2 by a chloride-sensing mechanism involving the WNK3 and SPAK kinases.","date":"2008","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/18550832","citation_count":195,"is_preprint":false},{"pmid":"16275911","id":"PMC_16275911","title":"WNK3 modulates transport of Cl- in and out of cells: implications for control of cell volume and neuronal excitability.","date":"2005","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/16275911","citation_count":175,"is_preprint":false},{"pmid":"16275913","id":"PMC_16275913","title":"WNK3 kinase is a positive regulator of NKCC2 and NCC, renal cation-Cl- cotransporters required for normal blood pressure homeostasis.","date":"2005","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/16275913","citation_count":152,"is_preprint":false},{"pmid":"16446421","id":"PMC_16446421","title":"WNK3 bypasses the tonicity requirement for K-Cl cotransporter activation via a phosphatase-dependent pathway.","date":"2006","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/16446421","citation_count":104,"is_preprint":false},{"pmid":"26069258","id":"PMC_26069258","title":"Inhibition of WNK3 Kinase Signaling Reduces Brain Damage and Accelerates Neurological Recovery After Stroke.","date":"2015","source":"Stroke","url":"https://pubmed.ncbi.nlm.nih.gov/26069258","citation_count":86,"is_preprint":false},{"pmid":"21813709","id":"PMC_21813709","title":"With-No-Lysine Kinase 3 (WNK3) stimulates glioma invasion by regulating cell volume.","date":"2011","source":"American journal of physiology. Cell physiology","url":"https://pubmed.ncbi.nlm.nih.gov/21813709","citation_count":56,"is_preprint":false},{"pmid":"16357011","id":"PMC_16357011","title":"WNK3, a kinase related to genes mutated in hereditary hypertension with hyperkalaemia, regulates the K+ channel ROMK1 (Kir1.1).","date":"2005","source":"The Journal of physiology","url":"https://pubmed.ncbi.nlm.nih.gov/16357011","citation_count":51,"is_preprint":false},{"pmid":"15194194","id":"PMC_15194194","title":"Cloning, genomic organization, alternative splicing and expression analysis of the human gene WNK3 (PRKWNK3).","date":"2004","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/15194194","citation_count":50,"is_preprint":false},{"pmid":"24019400","id":"PMC_24019400","title":"Dietary salt intake regulates WNK3-SPAK-NKCC1 phosphorylation cascade in mouse aorta through angiotensin II.","date":"2013","source":"Hypertension (Dallas, Tex. : 1979)","url":"https://pubmed.ncbi.nlm.nih.gov/24019400","citation_count":50,"is_preprint":false},{"pmid":"19470686","id":"PMC_19470686","title":"Renal and brain isoforms of WNK3 have opposite effects on NCCT expression.","date":"2009","source":"Journal of the American Society of Nephrology : JASN","url":"https://pubmed.ncbi.nlm.nih.gov/19470686","citation_count":45,"is_preprint":false},{"pmid":"23213404","id":"PMC_23213404","title":"A minor role of WNK3 in regulating phosphorylation of renal NKCC2 and NCC co-transporters in vivo.","date":"2011","source":"Biology open","url":"https://pubmed.ncbi.nlm.nih.gov/23213404","citation_count":45,"is_preprint":false},{"pmid":"16501604","id":"PMC_16501604","title":"Protein kinase WNK3 increases cell survival in a caspase-3-dependent pathway.","date":"2006","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/16501604","citation_count":40,"is_preprint":false},{"pmid":"22179001","id":"PMC_22179001","title":"WNK3 is a putative chloride-sensing kinase.","date":"2011","source":"Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/22179001","citation_count":34,"is_preprint":false},{"pmid":"26861815","id":"PMC_26861815","title":"Deletion of the WNK3-SPAK kinase complex in mice improves radiographic and clinical outcomes in malignant cerebral edema after ischemic stroke.","date":"2016","source":"Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/26861815","citation_count":34,"is_preprint":false},{"pmid":"18768590","id":"PMC_18768590","title":"WNK3 positively regulates epithelial calcium channels TRPV5 and TRPV6 via a kinase-dependent pathway.","date":"2008","source":"American journal of physiology. Renal physiology","url":"https://pubmed.ncbi.nlm.nih.gov/18768590","citation_count":33,"is_preprint":false},{"pmid":"18701621","id":"PMC_18701621","title":"WNK3 and WNK4 amino-terminal domain defines their effect on the renal Na+-Cl- cotransporter.","date":"2008","source":"American journal of physiology. Renal physiology","url":"https://pubmed.ncbi.nlm.nih.gov/18701621","citation_count":33,"is_preprint":false},{"pmid":"23427142","id":"PMC_23427142","title":"Loss of WNK3 is compensated for by the WNK1/SPAK axis in the kidney of the mouse.","date":"2013","source":"American journal of physiology. Renal physiology","url":"https://pubmed.ncbi.nlm.nih.gov/23427142","citation_count":30,"is_preprint":false},{"pmid":"22415098","id":"PMC_22415098","title":"WNK3-SPAK interaction is required for the modulation of NCC and other members of the SLC12 family.","date":"2012","source":"Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/22415098","citation_count":30,"is_preprint":false},{"pmid":"32589890","id":"PMC_32589890","title":"Activated WNK3 induced by intracerebral hemorrhage deteriorates brain injury maybe via WNK3/SPAK/NKCC1 pathway.","date":"2020","source":"Experimental neurology","url":"https://pubmed.ncbi.nlm.nih.gov/32589890","citation_count":28,"is_preprint":false},{"pmid":"21613606","id":"PMC_21613606","title":"Similar effects of all WNK3 variants on SLC12 cotransporters.","date":"2011","source":"American journal of physiology. Cell physiology","url":"https://pubmed.ncbi.nlm.nih.gov/21613606","citation_count":24,"is_preprint":false},{"pmid":"22864523","id":"PMC_22864523","title":"Influence of WNK3 on intracellular chloride concentration and volume regulation in HEK293 cells.","date":"2012","source":"Pflugers Archiv : European journal of physiology","url":"https://pubmed.ncbi.nlm.nih.gov/22864523","citation_count":23,"is_preprint":false},{"pmid":"32579473","id":"PMC_32579473","title":"WNK3 and WNK4 exhibit opposite sensitivity with respect to cell volume and intracellular chloride concentration.","date":"2020","source":"American journal of physiology. Cell physiology","url":"https://pubmed.ncbi.nlm.nih.gov/32579473","citation_count":22,"is_preprint":false},{"pmid":"24920754","id":"PMC_24920754","title":"WNK3 abrogates the NEDD4-2-mediated inhibition of the renal Na+-Cl- cotransporter.","date":"2014","source":"American journal of physiology. Renal physiology","url":"https://pubmed.ncbi.nlm.nih.gov/24920754","citation_count":22,"is_preprint":false},{"pmid":"23482566","id":"PMC_23482566","title":"LINGO-1 receptor promotes neuronal apoptosis by inhibiting WNK3 kinase activity.","date":"2013","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/23482566","citation_count":21,"is_preprint":false},{"pmid":"34863180","id":"PMC_34863180","title":"Silencing of the lncRNA H19 enhances sensitivity to X-ray and carbon-ions through the miR-130a-3p /WNK3 signaling axis in NSCLC cells.","date":"2021","source":"Cancer cell international","url":"https://pubmed.ncbi.nlm.nih.gov/34863180","citation_count":21,"is_preprint":false},{"pmid":"23027929","id":"PMC_23027929","title":"Protein kinase WNK3 regulates the neuronal splicing factor Fox-1.","date":"2012","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/23027929","citation_count":16,"is_preprint":false},{"pmid":"36357569","id":"PMC_36357569","title":"WNK3 inhibition elicits antitumor immunity by suppressing PD-L1 expression on tumor cells and activating T-cell function.","date":"2022","source":"Experimental & molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/36357569","citation_count":8,"is_preprint":false},{"pmid":"30253317","id":"PMC_30253317","title":"Increased expression of WNK3 in dispersed granule cells in hippocampal sclerosis of mesial temporal lobe epilepsy patients.","date":"2018","source":"Epilepsy research","url":"https://pubmed.ncbi.nlm.nih.gov/30253317","citation_count":8,"is_preprint":false},{"pmid":"35678782","id":"PMC_35678782","title":"Rare pathogenic variants in WNK3 cause X-linked intellectual disability.","date":"2022","source":"Genetics in medicine : official journal of the American College of Medical Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/35678782","citation_count":7,"is_preprint":false},{"pmid":"34626749","id":"PMC_34626749","title":"WNK3 Promotes Neuronal Survival after Traumatic Brain Injury in Rats.","date":"2021","source":"Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/34626749","citation_count":4,"is_preprint":false},{"pmid":"27467688","id":"PMC_27467688","title":"WNK3 Kinase Enhances the Sodium Chloride Cotransporter Expression via an ERK 1/2 Signaling Pathway.","date":"2016","source":"Nephron","url":"https://pubmed.ncbi.nlm.nih.gov/27467688","citation_count":3,"is_preprint":false},{"pmid":"36311015","id":"PMC_36311015","title":"WNK3 kinase maintains neuronal excitability by reducing inwardly rectifying K+ conductance in layer V pyramidal neurons of mouse medial prefrontal cortex.","date":"2022","source":"Frontiers in molecular neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/36311015","citation_count":3,"is_preprint":false},{"pmid":"34858138","id":"PMC_34858138","title":"WNK3 Maintains the GABAergic Inhibitory Tone, Synaptic Excitation and Neuronal Excitability via Regulation of KCC2 Cotransporter in Mature Neurons.","date":"2021","source":"Frontiers in molecular neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/34858138","citation_count":3,"is_preprint":false},{"pmid":"34513083","id":"PMC_34513083","title":"WNK3 promotes the invasiveness of glioma cell lines under hypoxia by inducing the epithelial-to-mesenchymal transition.","date":"2021","source":"Translational neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/34513083","citation_count":2,"is_preprint":false},{"pmid":"35163434","id":"PMC_35163434","title":"Kinome-Wide Profiling Identifies Human WNK3 as a Target of Cajanin Stilbene Acid from Cajanus cajan (L.) Millsp.","date":"2022","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/35163434","citation_count":2,"is_preprint":false},{"pmid":"35273702","id":"PMC_35273702","title":"WNK3-PER1 interactions regulate the circadian rhythm in the suprachiasmatic nucleus in rats.","date":"2022","source":"American journal of translational research","url":"https://pubmed.ncbi.nlm.nih.gov/35273702","citation_count":2,"is_preprint":false},{"pmid":"40602592","id":"PMC_40602592","title":"ZFHX3 silencing alleviates ischemic stroke by suppressing pericyte contraction and calcium influx through inhibiting WNK3 expression.","date":"2025","source":"Experimental neurology","url":"https://pubmed.ncbi.nlm.nih.gov/40602592","citation_count":1,"is_preprint":false},{"pmid":"40993905","id":"PMC_40993905","title":"Increased expression of WNK3 during the perinatal period in newborn rats with hypoxic-ischemic encephalopathy.","date":"2025","source":"Brain injury","url":"https://pubmed.ncbi.nlm.nih.gov/40993905","citation_count":0,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":23442,"output_tokens":7557,"usd":0.091841,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":16729,"output_tokens":6281,"usd":0.120335,"stage2_stop_reason":"end_turn"},"total_usd":0.212176,"stage1_batch_id":"msgbatch_01UT1AahFPCAyn2uVweS7A9z","stage2_batch_id":"msgbatch_01HuKWtKNT4Pqj1bc8eEP5RV","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2005,\n      \"finding\": \"Kinase-active WNK3 increases Cl- influx via NKCC1 and inhibits Cl- exit through KCC1 and KCC2; kinase-inactive WNK3 has opposite effects. WNK3 effects are imparted via altered phosphorylation and surface expression of its downstream targets and bypass the normal requirement of altered tonicity for activation of these transporters.\",\n      \"method\": \"Heterologous expression in Xenopus laevis oocytes; kinase-inactive mutant studies; phosphorylation and surface expression assays\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal gain/loss-of-function experiments with kinase-inactive mutant, multiple transporters tested, replicated across related papers\",\n      \"pmids\": [\"16275911\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Kinase-active WNK3 potently activates both NKCC2 and NCC-mediated transport; kinase-inactive WNK3 potently inhibits both. WNK3 regulates these transporters by altering their expression at the plasma membrane and increases phosphorylation of NKCC2 at Thr-184 and Thr-189.\",\n      \"method\": \"Coexpression studies in Xenopus oocytes; kinase-inactive mutant; plasma membrane expression assays; phosphorylation assays\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — kinase-active vs. kinase-inactive mutants, surface expression and phosphorylation measured, multiple transporters, replicated in independent labs\",\n      \"pmids\": [\"16275913\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"WNK3 completely prevents cell swelling-induced activation of KCC1-KCC4 in Xenopus oocytes. Catalytically inactive WNK3 abolishes cell shrinkage-induced inhibition of KCC1-KCC4, resulting in >100-fold stimulation of K-Cl cotransport. This activation is abolished by calyculin A and cyclosporine A (protein phosphatase 1 and 2B inhibitors), indicating WNK3 acts via a phosphatase-dependent pathway to regulate KCCs.\",\n      \"method\": \"Heterologous expression in Xenopus oocytes; kinase-inactive mutant; pharmacological phosphatase inhibitors (calyculin A, cyclosporine A)\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — kinase-active and kinase-inactive mutants tested on multiple KCC isoforms, phosphatase involvement validated with two pharmacological inhibitors\",\n      \"pmids\": [\"16446421\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Intracellular chloride depletion activates NKCC2 by promoting phosphorylation of three conserved threonines (T96, T101, T111). This chloride-sensitive activation requires WNK3 upstream of SPAK; elimination of WNK3's SPAK-binding motif prevents NKCC2 activation, as does catalytically inactive WNK3.\",\n      \"method\": \"Heterologous expression in Xenopus laevis oocytes; KCC2 co-expression and hypotonic stress for Cl- depletion; threonine-to-alanine mutagenesis; SPAK-binding motif deletion; kinase-inactive mutant\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — mutagenesis of phosphorylation sites and binding motifs with functional readouts, multiple orthogonal approaches in one rigorous study\",\n      \"pmids\": [\"18550832\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"WNK3 inhibits the renal K+ channel ROMK1 >5.5-fold by reducing its plasmalemmal surface expression. This inhibition is independent of WNK3's catalytic activity and is mediated by WNK3's carboxyl terminus. A kinase-inactivating point mutation enhances ROMK1 inhibition >2.5-fold. WNK3 had no effect on paracellular Cl- flux or ENaC-mediated currents.\",\n      \"method\": \"Coexpression in Xenopus laevis oocytes; kinase-inactive and domain mutants; MDCK II paracellular flux assay; surface expression analysis\",\n      \"journal\": \"The Journal of physiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal gain/loss-of-function, domain mapping, multiple channel targets tested with controls, specificity shown by negative result on KCNQ1/KCNE1\",\n      \"pmids\": [\"16357011\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Endogenous WNK3 is an active protein kinase when immunoprecipitated from cells. WNK3 overexpression increases HeLa cell survival by delaying apoptosis onset; WNK3 knockdown by RNAi accelerates apoptotic response and promotes caspase-3 activation. The mechanism involves interaction of WNK3 with procaspase-3 and heat-shock protein 70.\",\n      \"method\": \"Immunoprecipitation kinase assay; overexpression; RNAi knockdown; caspase-3 activation assays; co-immunoprecipitation with procaspase-3 and HSP70\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — endogenous kinase activity confirmed by IP-kinase assay, RNAi and overexpression with functional readout, co-IP binding partners identified, single lab\",\n      \"pmids\": [\"16501604\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"WNK3 positively regulates TRPV5 and TRPV6 epithelial calcium channels in a kinase-dependent manner, increasing TRPV5-mediated Ca2+ uptake by ~83%. The kinase domain alone is sufficient; D294A kinase-inactive mutation abolishes the effect. WNK3 increases the complexly glycosylated, plasma membrane-expressed form of TRPV5 via enhanced delivery through the secretory pathway, blocked by microtubule inhibitor colchicine.\",\n      \"method\": \"Coexpression in Xenopus laevis oocytes; kinase-inactive D294A mutant; kinase domain truncation; Ca2+ uptake assay; voltage-clamp; plasma membrane expression and exocytosis assays; colchicine treatment\",\n      \"journal\": \"American journal of physiology. Renal physiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — reconstitution in oocytes with mutagenesis (D294A), domain deletion, trafficking assay with pharmacological inhibitor, multiple orthogonal methods in one study\",\n      \"pmids\": [\"18768590\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"The amino-terminal domain of WNK3 (not the kinase or carboxyl domain) determines whether a WNK kinase activates or inhibits NCC. Chimeras swapping amino- or carboxyl-terminal domains between WNK3 and WNK4 show that the amino terminus governs activating vs. inhibiting properties toward NCC.\",\n      \"method\": \"WNK3/WNK4 chimera construction and coexpression in Xenopus oocytes; NCC transport assays\",\n      \"journal\": \"American journal of physiology. Renal physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — domain-swap chimeras with functional readout, multiple chimera constructs, single lab\",\n      \"pmids\": [\"18701621\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Renal and brain splice isoforms of WNK3 (differing by exons 18 and 22) have opposite effects on NCC: the renal isoform increases NCC expression/activity while the brain isoform decreases it. Kinase-inactivating mutation in renal WNK3 reverses its effect. Brain WNK3 acts in tandem with SPAK, whereas renal WNK3 upregulates NCC through a SPAK-independent pathway.\",\n      \"method\": \"Expression in Xenopus oocytes; kinase-dead mutant; kinase-dead SPAK coexpression; NCC surface expression and transport assays\",\n      \"journal\": \"Journal of the American Society of Nephrology : JASN\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple splice variants compared, kinase-dead mutants, SPAK-dependence tested, single lab\",\n      \"pmids\": [\"19470686\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"WNK3 knockout mice show no significant decrease in phosphorylation or expression of OSR1, SPAK, NKCC2, or NCC under normal or low-salt diets, indicating WNK3 has only a minor role in regulating these transporters in vivo in the kidney. WNK1 expression was slightly elevated in knockout mice on low-salt diet, suggesting compensatory upregulation.\",\n      \"method\": \"WNK3 knockout mouse generation; immunoblotting for pOSR1, pSPAK, pNKCC2, pNCC; urine electrolyte measurements; blood pressure measurement\",\n      \"journal\": \"Biology open\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic knockout with multiple molecular and physiological readouts; negative result for renal transporter phosphorylation is itself mechanistically informative, single lab\",\n      \"pmids\": [\"23213404\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"In glioma cells, WNK3 co-localizes and co-immunoprecipitates with NKCC1 upon cell volume changes. Stable knockdown of WNK3 completely abolishes bumetanide-sensitive NKCC1 activity and reduces invasive capacity across Transwell barriers.\",\n      \"method\": \"Co-immunoprecipitation; shRNA knockdown; bumetanide-sensitive cell volume regulation assay; Transwell invasion assay\",\n      \"journal\": \"American journal of physiology. Cell physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP plus functional shRNA knockdown with two orthogonal readouts (volume regulation and invasion), single lab\",\n      \"pmids\": [\"21813709\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"WNK3 binds Fox-1 (neuronal mRNA splicing factor) and inhibits its splicing activity in a kinase activity-dependent manner. WNK3 phosphorylates Fox-1 without changing its RNA binding capacity; instead, WNK3 increases the cytoplasmic localization of Fox-1, thereby suppressing Fox-1-dependent splicing.\",\n      \"method\": \"Co-immunoprecipitation; in vitro phosphorylation assay; subcellular localization studies; splicing reporter assays; kinase-inactive mutant comparisons\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — binding confirmed by co-IP, phosphorylation shown, subcellular redistribution measured, functional splicing readout, single lab\",\n      \"pmids\": [\"23027929\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"WNK3's effects on NCC and other CCCs require interaction with SPAK via specific RFxV binding motifs. The F242A mutation in the first SPAK-binding site of WNK3 abolishes effects on all tested cotransporters; F1337A eliminates effect on NKCC2 but preserves effects on NCC, NKCC1, and KCC4; F873A has no consequence. WNK3 can promote NCC phosphorylation at T58 even without the NCC SPAK-binding site, suggesting WNK3 binds both SPAK and NCC to promote phosphorylation.\",\n      \"method\": \"Site-directed mutagenesis of SPAK binding motifs; expression in Xenopus laevis oocytes; transport assays; phosphorylation assays\",\n      \"journal\": \"Cellular physiology and biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — systematic mutagenesis of three binding sites with functional readouts on multiple cotransporters, mechanistic conclusions supported by multiple mutants, single lab\",\n      \"pmids\": [\"22415098\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"In mouse aorta, the WNK3-SPAK-NKCC1 phosphorylation cascade is regulated by dietary salt intake through angiotensin II acting via the AT1 receptor. In WNK3 knockout mice, low-salt diet and angiotensin II infusion fail to increase SPAK/NKCC1 phosphorylation, demonstrating WNK3 dependence. Angiotensin II-induced blood pressure increases are diminished in WNK3 knockout mice.\",\n      \"method\": \"WNK3 knockout mice; dietary salt manipulation; angiotensin II infusion; AT1 receptor antagonist (valsartan); immunoblotting for pSPAK, pNKCC1; blood pressure measurement\",\n      \"journal\": \"Hypertension\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic knockout with pharmacological validation, multiple physiological readouts, receptor antagonist used to place WNK3 downstream of AT1, single lab but multiple orthogonal approaches\",\n      \"pmids\": [\"24019400\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"LINGO-1 co-localizes and co-precipitates with WNK3 in cultured cortical neurons and brain tissue. Nogo66 stimulation enhances this co-association and reduces WNK3 kinase activity. LINGO-1 binding to WNK3's intracellular domain reduces WNK3 kinase activity, thereby promoting neuronal apoptosis.\",\n      \"method\": \"Co-immunoprecipitation; co-localization immunofluorescence; kinase activity assay; shRNA knockdown; Nogo66 stimulation; LINGO-1 intracellular domain construct\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal co-IP, kinase activity assay, in vitro and in vivo evidence, single lab with multiple methods\",\n      \"pmids\": [\"23482566\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"In WNK3-deficient mice, WNK1 is markedly upregulated while WNK4 expression remains similar, indicating that WNK1/SPAK axis compensates for WNK3 loss in the kidney. Under low-salt diet, pSPAK/OSR1, pNKCC2, and pNCC levels in WNK3-/- exceed those in wild-type, confirming compensatory activation of WNK3-independent pathways.\",\n      \"method\": \"WNK3 knockout mice; immunoblotting for WNK1, WNK4, pSPAK/OSR1, pNKCC2, pNCC; hydrochlorothiazide diuretic response; dietary salt manipulation\",\n      \"journal\": \"American journal of physiology. Renal physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic knockout with molecular and pharmacological validation, single lab\",\n      \"pmids\": [\"23427142\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"NEDD4-2 was identified as a WNK3-interacting partner via GST pulldown of WNK3's N-terminal domain followed by LC-MS/MS, validated by co-immunoprecipitation in HEK293 cells. WNK3 interaction with NEDD4-2 does not involve the PY-like motif. WNK3 does not ubiquitylate NEDD4-2 or phosphorylate NEDD4-2 on S222/S328, and does not regulate NCC-NEDD4-2 interaction. WNK3 can overcome SGK1-resistant NEDD4-2-mediated inhibition of NCC via a SPAK-independent mechanism (F242A mutation blocks NCC activation but not NEDD4-2 inhibitory reversal).\",\n      \"method\": \"GST pulldown with LC-MS/MS; co-immunoprecipitation in HEK293 cells; ubiquitylation assay; phosphorylation assay; Xenopus oocyte expression with SPAK-binding mutant WNK3-F242A\",\n      \"journal\": \"American journal of physiology. Renal physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — GST pulldown/MS plus co-IP validation, functional oocyte assays with domain mutant, single lab, multiple orthogonal methods\",\n      \"pmids\": [\"24920754\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"In ischemic stroke (transient MCAO), WNK3 knockout mice exhibit significantly decreased infarct volume and axonal demyelination, reduced cerebral edema, and accelerated neurological recovery. The neuroprotective phenotype is associated with decreased hyperphosphorylation of SPAK/OSR1 catalytic T-loop and of NKCC1 stimulatory sites Thr203/Thr207/Thr212, and decreased cell surface expression of NKCC1. siRNA knockdown of SPAK/OSR1 also increased tolerance of neurons and oligodendrocytes to in vitro ischemia, confirming WNK3-SPAK/OSR1-NKCC1 as the operative cascade.\",\n      \"method\": \"WNK3 knockout mice; transient MCAO; infarct volume, edema, demyelination assessment; immunoblotting and immunostaining for pSPAK/OSR1, pNKCC1, NKCC1 surface expression; oxygen-glucose deprivation/reoxygenation in neurons and oligodendrocytes; siRNA knockdown\",\n      \"journal\": \"Stroke\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic knockout plus siRNA knockdown of downstream target, molecular readouts of the cascade, in vitro and in vivo concordant evidence, multiple cell types\",\n      \"pmids\": [\"26069258\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"WNK3 enhances NCC protein expression by increasing NCC protein synthesis (not via lysosomal degradation pathway). WNK3 reduces ERK1/2 phosphorylation, and knockdown of ERK1/2 expression reverses WNK3-mediated increase in NCC, indicating WNK3 acts through an ERK1/2 signaling pathway to upregulate NCC.\",\n      \"method\": \"Overexpression and siRNA knockdown in Cos-7 and mouse distal convoluted tubule cells; cycloheximide pulse-chase assay; bafilomycin A1 treatment; ERK1/2 knockdown; Western blot\",\n      \"journal\": \"Nephron\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple pharmacological and genetic interventions, CHX pulse assay establishes synthesis mechanism, ERK1/2 knockdown confirms pathway, single lab\",\n      \"pmids\": [\"27467688\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Deletion of the WNK3-SPAK kinase complex in mice (WNK3 KO and SPAK heterozygous or KO) each produce >50% reduction in infarct size and cerebral edema, significantly less demyelination, and improved neurological outcomes after MCAO stroke, establishing the WNK3-SPAK complex as the operative signaling unit mediating ischemic brain injury.\",\n      \"method\": \"WNK3 KO, SPAK heterozygous and SPAK KO mice; transient MCAO; MRI diffusion tensor imaging; immunofluorescence; neurological deficit scoring up to 14 days\",\n      \"journal\": \"Journal of cerebral blood flow and metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic evidence from three distinct mouse genotypes (WNK3 KO, SPAK het, SPAK KO) with concordant results, multiple imaging and behavioral readouts\",\n      \"pmids\": [\"26861815\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"WNK3 is not sensitive to intracellular chloride concentration but is regulated by changes in extracellular tonicity (cell volume changes). Elimination of the chloride-binding site in WNK3 does not affect its activity toward NCC. Chimeric WNK3/WNK4 analysis suggests sequences within the carboxy-terminal end modulate chloride affinity. In contrast, WNK4 is chloride-sensitive but not regulated by cell volume.\",\n      \"method\": \"Xenopus oocyte expression system; chloride-binding site mutagenesis; WNK3/WNK4 chimeric protein constructs; tonicity and Cl- concentration manipulation; NCC transport assays\",\n      \"journal\": \"American journal of physiology. Cell physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — chimera domain mapping plus active-site mutagenesis, functional assays with controlled conditions, single lab\",\n      \"pmids\": [\"32579473\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"WNK3 knockdown in hippocampal neurons hyperpolarizes the GABAA reversal potential (EGABA) in mature (DIV13-15) but not immature (DIV6-8) neurons. This effect is mediated through reduced phosphorylation of KCC2 at the membrane (increased KCC2 activity), reversed by KCC2 inhibitor VU024055. WNK3 knockdown also causes morphological changes and increased intrinsic excitability in mature neurons.\",\n      \"method\": \"shRNA knockdown in embryonic hippocampal neurons; gramicidin-perforated patch-clamp; immunoblotting for KCC2 phosphorylation; KCC2 inhibitor (VU024055); membrane surface expression analysis\",\n      \"journal\": \"Frontiers in molecular neuroscience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — electrophysiology combined with biochemical and pharmacological rescue, single lab, multiple methods\",\n      \"pmids\": [\"34858138\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"WNK3 knockout mice show elevated intracellular Cl- in layer V prefrontal cortex pyramidal neurons (EGABA depolarized by 6 mV, corresponding to ~4 mM higher [Cl-]i). KO neurons exhibit increased inwardly rectifying K+ (Kir channel) conductance, hyperpolarized resting membrane potential, and increased firing threshold. Introducing active WNK3 into KO neurons reverses these changes. The KCC2 activator CLP290 reverses enhanced IRK conductance in KO neurons, linking WNK3 and KCC2 in resting K+ conductance regulation. WNK3 KO mice show behavioral deficits in prepulse inhibition.\",\n      \"method\": \"WNK3 KO mice; gramicidin-perforated patch-clamp in acute slices; intracellular active WNK3 injection; CLP290 (KCC2 activator); immunoblotting for pSPAK, pOSR1, pNKCC1, pKCC2; mEPSC/mIPSC recording; prepulse inhibition behavioral test\",\n      \"journal\": \"Frontiers in molecular neuroscience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO with electrophysiology, pharmacological rescue, and acute kinase reintroduction, multiple orthogonal methods, single lab\",\n      \"pmids\": [\"36311015\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"WNK3 pathogenic missense variants (p.Pro204Arg, p.Leu300Ser, p.Glu607Val) localize to the catalytic domain and impede the inhibitory phosphorylation of neuronal KCC2 at threonine 1007, a site critically regulated during development of synaptic inhibition, causing X-linked intellectual disability.\",\n      \"method\": \"Exome/genome sequencing of intellectual disability families; functional assays of KCC2 T1007 phosphorylation with disease-associated WNK3 variants\",\n      \"journal\": \"Genetics in medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — disease-causing variants tested in functional phosphorylation assay, multiple families with cosegregation, mechanistic link to KCC2 phosphorylation established\",\n      \"pmids\": [\"35678782\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"WNK3 is a positive regulator of PD-L1 expression in tumor cells via a kinase-dependent mechanism. Kinase-dead WNK3 mutant fails to elevate PD-L1 levels. WNK3 regulates PD-L1 transcription through the JNK/c-JUN pathway.\",\n      \"method\": \"Pooled shRNA screening; kinase-dead mutant; co-culture of cancer and immune cells; cytokine and cytolytic enzyme secretion assays; WNK463 pan-WNK inhibitor; MC38 syngeneic mouse tumor model; c-JUN pathway analysis\",\n      \"journal\": \"Experimental & molecular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — shRNA screen validated with kinase-dead mutant and pharmacological inhibitor, in vivo syngeneic model, pathway identification via c-JUN, single lab\",\n      \"pmids\": [\"36357569\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"WNK3 co-localizes and interacts with the circadian clock protein PER1 in the suprachiasmatic nucleus. WNK3 phosphorylates PER1 to promote its degradation. WNK3 knockdown in rat SCN alters sleep patterns.\",\n      \"method\": \"Co-localization and co-immunoprecipitation in SCN; in vitro kinase assay (PER1 phosphorylation); shRNA knockdown in vivo; sleep pattern analysis\",\n      \"journal\": \"American journal of translational research\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, co-IP plus in vitro phosphorylation, limited mechanistic follow-up, abstract-level description of methods\",\n      \"pmids\": [\"35273702\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"WNK3 is a serine-threonine kinase that acts as a master regulator of intracellular chloride homeostasis and cell volume by coordinately activating Na-(K)-Cl cotransporters (NKCC1, NKCC2, NCC) and inhibiting K-Cl cotransporters (KCC1–KCC4) through its kinase activity and interaction with the downstream SPAK/OSR1 kinases via RFxV binding motifs; it also regulates ROMK1 surface expression via a kinase-independent carboxyl-terminal mechanism, modulates neuronal Fox-1 splicing factor localization, promotes cell survival by interacting with procaspase-3, regulates PD-L1 via JNK/c-JUN signaling, phosphorylates the circadian protein PER1, and mediates ischemic brain edema through the WNK3-SPAK-NKCC1 cascade, with loss-of-function variants in its catalytic domain causing X-linked intellectual disability through impaired KCC2 phosphorylation.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"WNK3 is a serine-threonine protein kinase that functions as a coordinate regulator of cation-chloride cotransporters, setting intracellular chloride concentration and cell volume by reciprocally controlling Na-(K)-Cl cotransporters and K-Cl cotransporters: kinase-active WNK3 activates NKCC1, NKCC2 and NCC by increasing their surface expression and stimulatory-site phosphorylation while inhibiting KCC1\\u2013KCC4, and the catalytically inactive kinase produces the opposite effects, bypassing the normal tonicity requirement for transporter activation [#0, #1, #2]. Its activation of cotransporters operates upstream of the SPAK/OSR1 kinases through RFxV-type binding motifs, where site-specific mutations (F242A, F1337A) selectively abolish effects on individual cotransporters, and WNK3 promotes target phosphorylation by binding both SPAK and the cotransporter [#3, #12]. WNK3 itself is regulated by extracellular tonicity/cell volume rather than by direct intracellular chloride sensing, distinguishing it from chloride-sensitive WNK4 [#20]. In neurons WNK3 controls GABAergic signaling by restraining KCC2 via inhibitory phosphorylation, so its loss hyperpolarizes the GABAA reversal potential and lowers intracellular chloride, and pathogenic catalytic-domain missense variants that impair KCC2 Thr1007 phosphorylation cause X-linked intellectual disability [#21, #22, #23]. The WNK3-SPAK-NKCC1 cascade also drives ischemic brain injury, as WNK3 or SPAK deletion reduces infarct volume, cerebral edema and demyelination after stroke [#17, #19]. Beyond its core cotransporter role, WNK3 regulates ROMK1 surface expression through a kinase-independent C-terminal mechanism [#4], activates TRPV5/TRPV6 calcium channels via the secretory pathway [#6], modulates renal NCC abundance through ERK1/2 and NEDD4-2 [#16, #18, #16], promotes cell survival through interaction with procaspase-3 [#5], regulates neuronal Fox-1 splicing-factor localization [#11], controls tumor PD-L1 via JNK/c-JUN signaling [#24], and phosphorylates the circadian protein PER1 [#25]; in vivo, however, renal cotransporter regulation is largely dispensable, with WNK1 compensating for WNK3 loss in the kidney [#9, #15].\",\n  \"teleology\": [\n    {\n      \"year\": 2005,\n      \"claim\": \"Established WNK3 as a bidirectional switch over chloride transport, answering whether a single kinase could coordinately activate Na-coupled and inhibit K-coupled chloride cotransporters.\",\n      \"evidence\": \"Kinase-active and kinase-inactive WNK3 expressed with NKCC1/NKCC2/NCC and KCC1\\u2013KCC2 in Xenopus oocytes with phosphorylation and surface-expression readouts\",\n      \"pmids\": [\"16275911\", \"16275913\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Performed in a heterologous oocyte system; physiological relevance in native tissue untested at this stage\", \"Direct vs. indirect phosphorylation of transporters not distinguished\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Showed WNK3 regulates KCCs through a phosphatase-dependent pathway, clarifying that WNK3 opposes the cell-volume-dependent dephosphorylation that activates K-Cl cotransport.\",\n      \"evidence\": \"Oocyte expression of KCC1\\u2013KCC4 with kinase-inactive WNK3 and PP1/PP2B inhibitors (calyculin A, cyclosporine A)\",\n      \"pmids\": [\"16446421\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the responsible phosphatase not pinned down\", \"Whether WNK3 acts directly on the phosphatase or on the transporter unresolved\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Defined a kinase-independent function of WNK3, distinguishing its catalytic activity from a separate C-terminal mechanism that suppresses ROMK1 surface expression.\",\n      \"evidence\": \"Coexpression of ROMK1 with kinase-inactive and domain-mutant WNK3 in oocytes, with paracellular and ENaC controls\",\n      \"pmids\": [\"16357011\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"C-terminal effector mediating ROMK1 trafficking not identified\", \"Physiological role in renal K+ handling untested\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Demonstrated endogenous WNK3 kinase activity and a pro-survival role, expanding WNK3 function beyond ion transport into apoptosis regulation.\",\n      \"evidence\": \"IP-kinase assay, overexpression/RNAi in HeLa cells with caspase-3 readout, and co-IP with procaspase-3 and HSP70\",\n      \"pmids\": [\"16501604\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether WNK3 phosphorylates procaspase-3 not established\", \"Single-lab co-IP without reciprocal or structural validation\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Established WNK3 as an upstream component of a chloride-sensitive SPAK cascade and mapped phosphorylation sites, defining the signaling architecture controlling NKCC2.\",\n      \"evidence\": \"Oocyte expression with NKCC2 threonine-to-alanine mutagenesis, SPAK-binding motif deletion, and kinase-inactive WNK3\",\n      \"pmids\": [\"18550832\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct phosphorylation of SPAK by WNK3 not shown biochemically here\", \"In vivo chloride-sensing mechanism unresolved\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Localized the activating-vs-inhibiting determinant to the WNK3 amino-terminal domain and showed kinase-dependent positive regulation of TRPV5/TRPV6, broadening WNK3 targets to calcium channels.\",\n      \"evidence\": \"WNK3/WNK4 chimeras and NCC assays; oocyte TRPV5/TRPV6 Ca2+ uptake with D294A mutant, domain truncation, and colchicine\",\n      \"pmids\": [\"18701621\", \"18768590\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular basis by which the N-terminus dictates activating vs inhibiting output not defined\", \"Whether TRPV channels are direct substrates unknown\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Revealed isoform-specific and SPAK-dependence differences, showing renal and brain WNK3 splice variants exert opposite effects on NCC through distinct pathways.\",\n      \"evidence\": \"Oocyte expression of renal vs brain WNK3 isoforms with kinase-dead WNK3 and kinase-dead SPAK coexpression\",\n      \"pmids\": [\"19470686\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism by which exons 18/22 invert function not resolved\", \"Tissue isoform expression patterns not validated in vivo\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Tested the in vivo requirement for WNK3 in renal transporter regulation and found it largely dispensable, prompting a compensation model.\",\n      \"evidence\": \"WNK3 knockout mice with immunoblotting of pSPAK/OSR1/NKCC2/NCC, urine electrolytes, and blood pressure under salt diets\",\n      \"pmids\": [\"23213404\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Compensatory mechanism only inferred from WNK1 upregulation\", \"Possible developmental compensation not excluded\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Linked WNK3-NKCC1 signaling to a disease-relevant cellular behavior, showing WNK3 supports volume regulation and invasion in glioma.\",\n      \"evidence\": \"Co-IP of WNK3 with NKCC1 plus shRNA knockdown with bumetanide-sensitive volume and Transwell invasion assays\",\n      \"pmids\": [\"21813709\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether invasion effect is solely NKCC1-dependent unclear\", \"Single-lab functional data\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Mapped the RFxV SPAK-binding motifs that govern target selectivity and identified a non-canonical role in mRNA splicing, defining how WNK3 selects among cotransporters and uncovering Fox-1 regulation.\",\n      \"evidence\": \"Systematic F242A/F1337A/F873A mutagenesis with cotransporter assays; co-IP, in vitro phosphorylation, and splicing reporters for Fox-1\",\n      \"pmids\": [\"22415098\", \"23027929\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How the same motifs confer different specificity for each cotransporter not fully explained\", \"Fox-1 splicing role tested in heterologous reporter context only\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Placed WNK3 downstream of angiotensin II/AT1 signaling in vasculature and identified an inhibitory kinase regulator, situating WNK3 within hormonal blood-pressure control and neuronal apoptosis.\",\n      \"evidence\": \"WNK3 KO mice with salt/AngII manipulation and valsartan; LINGO-1 co-IP, Nogo66 stimulation, and kinase-activity assays in neurons\",\n      \"pmids\": [\"24019400\", \"23482566\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct vascular substrate of the WNK3-SPAK-NKCC1 cascade not defined\", \"Mechanism by which LINGO-1 binding inhibits kinase activity unresolved\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Confirmed WNK1/SPAK axis compensation for renal WNK3 loss, reconciling robust oocyte effects with a minor in vivo kidney phenotype.\",\n      \"evidence\": \"WNK3 KO mice with immunoblotting of WNK1/WNK4 and phospho-transporters plus hydrochlorothiazide response under salt diets\",\n      \"pmids\": [\"23427142\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of WNK1 upregulation upon WNK3 loss not established\", \"Extent of functional redundancy across nephron segments unclear\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Identified NEDD4-2 as an N-terminal partner and showed WNK3 reverses NEDD4-2-mediated NCC inhibition through a non-catalytic, SPAK-independent route, distinguishing this from its canonical cascade.\",\n      \"evidence\": \"GST pulldown/LC-MS/MS and co-IP in HEK293; ubiquitylation/phosphorylation assays and oocyte assays with WNK3-F242A\",\n      \"pmids\": [\"24920754\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular mechanism by which WNK3 antagonizes NEDD4-2 not defined\", \"Single-lab interaction without structural mapping\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Established WNK3-SPAK/OSR1-NKCC1 as the operative cascade driving ischemic brain edema and injury, providing a therapeutic rationale.\",\n      \"evidence\": \"WNK3 KO mice with MCAO, infarct/edema/demyelination readouts, cascade phospho-immunoblotting, and OGD with SPAK/OSR1 siRNA in neurons/oligodendrocytes\",\n      \"pmids\": [\"26069258\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Upstream trigger activating WNK3 during ischemia not identified\", \"Cell-type-specific contributions not fully dissected\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Uncovered a transcriptional/translational arm of WNK3 NCC regulation via ERK1/2 and confirmed the WNK3-SPAK complex as the stroke effector unit using complementary genetics.\",\n      \"evidence\": \"Overexpression/knockdown in DCT cells with CHX pulse-chase and ERK1/2 knockdown; WNK3 KO, SPAK het and SPAK KO mice with MCAO and DTI imaging\",\n      \"pmids\": [\"27467688\", \"26861815\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How WNK3 lowers ERK1/2 phosphorylation mechanistically unknown\", \"Whether ERK1/2 arm operates in vivo not tested\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Redefined WNK3 regulation as cell-volume/tonicity-responsive rather than intracellular-chloride-sensitive, separating it mechanistically from WNK4.\",\n      \"evidence\": \"Oocyte NCC assays with WNK3 chloride-binding-site mutagenesis and WNK3/WNK4 chimeras under controlled tonicity and Cl-\",\n      \"pmids\": [\"32579473\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"The volume-sensing element within the C-terminus not identified\", \"Physiological signal coupling volume to WNK3 activity unknown\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Demonstrated WNK3 controls GABAergic chloride homeostasis in mature neurons via KCC2 phosphorylation, defining its role in synaptic inhibition development.\",\n      \"evidence\": \"shRNA knockdown in hippocampal neurons with perforated patch-clamp EGABA, KCC2 phospho-immunoblotting, and KCC2 inhibitor VU024055 rescue\",\n      \"pmids\": [\"34858138\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Why the effect is age-dependent (mature vs immature) not explained\", \"Direct WNK3 phosphorylation of KCC2 not shown biochemically here\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Extended WNK3-KCC2 regulation to intrinsic excitability and resting K+ conductance in cortical neurons and tied catalytic-domain variants to X-linked intellectual disability, establishing a disease mechanism.\",\n      \"evidence\": \"WNK3 KO mice with patch-clamp, active-WNK3 reintroduction, CLP290 rescue, and behavioral testing; ID-family sequencing with KCC2 T1007 phosphorylation assays of variants\",\n      \"pmids\": [\"36311015\", \"35678782\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Link between altered Cl-/excitability and cognitive phenotype not directly demonstrated\", \"Variant functional assays in patient-derived neurons not performed\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Identified additional kinase-dependent roles in tumor immune evasion and circadian regulation, broadening WNK3 substrates beyond ion transport.\",\n      \"evidence\": \"shRNA screen, kinase-dead mutant, WNK463 inhibitor and MC38 model with c-JUN analysis for PD-L1; co-IP and in vitro PER1 phosphorylation with SCN shRNA knockdown and sleep analysis\",\n      \"pmids\": [\"36357569\", \"35273702\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"PER1/circadian role rests on a single low-confidence study without reconstitution\", \"How WNK3 engages the JNK/c-JUN pathway to regulate PD-L1 transcription not mechanistically defined\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How extracellular tonicity is transduced into WNK3 catalytic activation, and how a single kinase achieves opposite, target-specific outputs across cotransporters, channels, and splicing/transcriptional substrates, remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No structural model of the volume-sensing C-terminus\", \"Mechanism converting one kinase into bidirectional transporter control unknown\", \"Direct vs indirect phosphorylation for several proposed substrates undetermined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0, 1, 3, 11, 23, 25]},\n      {\"term_id\": \"GO:0016740\", \"supporting_discovery_ids\": [0, 3, 5, 12]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [2, 4, 16]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [11]},\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [11]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-382551\", \"supporting_discovery_ids\": [0, 1, 2, 3, 6]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [13, 18, 24]},\n      {\"term_id\": \"R-HSA-112316\", \"supporting_discovery_ids\": [21, 22, 23]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [5, 14]}\n    ],\n    \"complexes\": [\"WNK3-SPAK kinase complex\"],\n    \"partners\": [\"SPAK\", \"OSR1\", \"NKCC1\", \"NCC\", \"KCC2\", \"NEDD4-2\", \"LINGO-1\", \"PER1\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":6,"faith_total":6,"faith_pct":100.0}}